Skip to main content

Latest news from EU institutions and bodies

Filtrer par

Latest news from EU institutions and bodies (382)

Résultats 1 sur 10
  • 8 février 2023

India: EIB backs green hydrogen deployment and joins India Hydrogen Alliance

In Mumbai Kris Peeters, Vice President of the European Investment Bank (EIB), the bank of the European Union, formally agreed today to join the India Hydrogen Alliance (IH2A) and increase support for large-scale green hydrogen hubs and projects across India with an indicative funding of EUR 1 billion, subject to Indian Government and EIB approvals.
  • 8 février 2023

Market Report on EU MMF market 2023

Market Report on EU MMF market 2023 iris.hude@esma… 08 February 2023 Image /press-news/esma-news/esma-report-finds-eu-mmf-industry-close-eu15tn ESMA report finds EU MMF industry at close to €1.5tn -3 Place Multiple row
  • 8 février 2023

ESMA report finds EU MMF industry at close to €1.5tn

ESMA report finds EU MMF industry at close to €1.5tn iris.hude@esma… 08 February 2023 Fund Management Risk monitoring The European Securities and Markets Authority (ESMA), the EU’s financial markets regulator and supervisor, today published its inaugural market report on European Union (EU) Money Market Funds (MMF). With this report ESMA provides for the first time a comprehensive market-level view of EU MMFs, based on supervisory information collected by National Competent Authorities (NCAs) and ESMA. Verena Ross, Chair, said: “MMFs play a central role in the financial system, by bringing together the demand for and supply of short-term funding, and are closely interconnected with other parts of the financial sector. Recent periods of stress experienced by MMFs in the short-term funding markets (such as in March 2020) have shown the importance of monitoring trends and developments in the EU MMF sector. The MMF Regulation introduced a reporting obligation for managers of MMFs to inform competent authorities’ supervisory activity, allowing ESMA to publish today the first overview of this market using regulatory data." The main findings included in today’s report are: EU MMF sector: The EU MMF sector had €1.44tn of assets in 2021, with 89% of the funds domiciled in France, Luxembourg and Ireland. Sector breakdown: Low-volatility NAV (LVNAV) MMFs account for 46% of the total assets, followed by Variable NAV (VNAV) MMFs (42%) and Constant NAV (CNAV) MMFs (12%). All MMFs domiciled in France are of the VNAV type and almost exclusively denominated in EUR. MMFs in Luxembourg and Ireland are mainly in non-EU currencies and set up mostly as CNAVs and LVNAVs. MMFs authorised in other EU jurisdictions are VNAVs denominated in other EU domestic currencies and account only for a small fraction of assets. Asset allocation: The portfolio structure of EU MMFs remains relatively stable over time, and they are mainly exposed to the financial sector. Between March 2020 and June 2022, average exposures to credit institutions amount to 60% of total assets. Most of the EU MMFs’ government debt exposure is towards non-EU sovereigns, and during March to December 2020 LVNAVs increased their share of government bonds before starting a slow readjustment back to the pre-COVID composition. Liquid assets and risk sensitivity: The share of daily and weekly liquid assets remained above the regulatory minimum, and increased for CNAVs at a regular pace starting in 3Q20. As of 3Q21, EU MMFs have significantly reduced the interest rate risk sensitivity of their portfolios, measured as the weighted average maturity of assets (WAM), to improve resilience to a rate rise. Ownership and liabilities: Professional investors hold more than 90% of EU MMFs. Financial corporations are the main unitholders of MMF shares, with insurance firms, pension funds and banks accounting together for 25% of NAV and other financial institutions, including collective investment undertakings, for 45% of the NAV. Between December 2021 and March 2022 MMFs experienced substantial outflows, partially driven by investor expectations linked to the increase in interest rates and a turning investor sentiment away from fixed income instruments in general, a trend that reversed later in 2022. In its opinion from February 2022, ESMA proposed that the European Commission should consider a number of changes to the MMF Regulation, intended to make MMFs more resilient. These reforms would help to improve the overall stability of financial markets, by reducing the risk of liquidity stress. Alongside key policy measures such as addressing the threshold effects for CNAV MMFs, and addressing liquidity related issues, ESMA suggested complementary reforms aimed at enhancing MMFs’ preparedness for a crisis.  These reforms would include enhancements of reporting requirements and the stress testing framework, as well as new disclosure requirements linked to the rating of MMFs.  ESMA has also highlighted the importance of having these changes to the MMF Regulation implemented speedily. ESMA will continue to monitor and analyse the risks in the MMF sector.   Further information:Solveig Kleiveland Acting Team Leader – Communications @ press@esma.europa.eu ✆ +33 1 58 36 43 27 08/02/2023 ESMA50-165-2391 ESMA Market Report on EU MMF market - 2023 08/02/2023 ESMA71-99-2093 ESMA report finds EU MMF industry at close to €1.5tn - Press Release
  • 8 février 2023

EIB publishes its approach to human rights

The European Investment Bank’s approach to human rights: Information note, published today, outlines the EIB’s commitment and approach to respecting and promoting human rights in its lending operations, presents the policies it has in place to fulfil this commitment, and describes how it addresses human rights risks and impacts in its investments. 
  • 8 février 2023

Estonia: InvestEU - EIB agrees €18 million loan to biotech Icosagen for innovative R&D technologies and new cGMP production facility

The Estonian biopharmaceutical innovator Icosagen AS has reached a €18 million financing agreement with the European Investment Bank (EIB) — backed by the InvestEU programme — to further strengthen its drug discovery, development and production services. The funds are part of Icosagen’s €40 million investment into increasing its innovative contract research and development capabilities as well as into a new current good manufacturing practice (cGMP) facility to produce innovative drugs for clinical trials.
  • 7 février 2023

The very visible value of intangible assets: why IP valuation matters

The protection of intellectual property (IP) is crucial to individual creators, inventors, designers, and companies alike. From big corporations to small and medium-sized enterprises (SMEs), IP assets represent an extremely significant portion of the overall value of any organisation. That is true not only when IP rights are being sold and purchased, but also when they are exploited through licensing and franchising.